Meridian Bioscience Stock

Meridian Bioscience FCF Yield

The Free Cash Flow Yield of Meridian Bioscience (VIVO) as of Sep 11, 2026 is 4.93 %. In the previous year, Free Cash Flow Yield was 3.25 % — a change of 51.89% (higher).

FCF Yield

4.93 %

YoY

51.89%

Last updated:

Free Cash Flow Yield of Meridian Bioscience is 2026 4.93 % . Free Cash Flow Yield of Meridian Bioscience was 2025 3.25 % . It decreases by 51.89% higher compared to the previous year.

The Meridian Bioscience FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2015
2.55 USD
Jan 1, 2016
2.22 USD
Jan 1, 2017
2.47 USD
Jan 1, 2018
2.05 USD
Jan 1, 2019
2.17 USD
Jan 1, 2020
2.99 USD
Jan 1, 2021
3.25 USD
Jan 1, 2022
4.93 USD
The Meridian Bioscience FCF Yield history
YEARFCF YieldYoY
4.93 %+51.89%
3.25 %+8.67%
2.99 %+37.99%
2.17 %+5.89%
2.05 %-17.10%
2.47 %+11.05%
2.22 %-12.69%
2.55 %+21.72%
2.09 %
Access this data via the Eulerpool API

Meridian Bioscience Stock analysis

What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Meridian Bioscience stock

Free Cash Flow Yield of Meridian Bioscience is 4.93 % in 2026.

Free Cash Flow Yield of Meridian Bioscience changed from 3.25 % to 4.93 %, representing a 51.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Meridian Bioscience since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Meridian Bioscience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Meridian Bioscience

All Key Metrics — Meridian Bioscience